Elsevier

Clinical Therapeutics

Volume 28, Issue 7, July 2006, Pages 1054-1062
Clinical Therapeutics

Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals

https://doi.org/10.1016/j.clinthera.2006.07.007Get rights and content

Abstract

Background:

Primary percutaneous coronary intervention ([PCI], percutaneous transluminal coronary angioplasty+stenting) for ST-segment elevation myocardial infarction (STEMI) is regarded as superior to fibrinolysis even if it means that patients need to be transferred from one center to another to undergo the procedure. However, this inevitable delay between symptom onset and PCI, caused by the time required to travel, might increase the occurrence of cardiac events. A hybrid method called facilitated PCI uses fibrinolysis and/or glycoprotein (GP) IIb/IIIa inhibitors before transfer to a tertiary medical center where urgent PCI might be performed. This approach, however, has not been systematically evaluated.

Objective:

The purpose of this study was to compare the effectiveness (combined end point of in-hospital mortality, reinfarction, stroke, or emergency revascularization) and cost-effectiveness of utilizing a bolus thrombolytic agent with GP IIb/IIIa inhibitor followed by transfer to a tertiary institution for facilitated PCI or standard of care transfer without primary PCI drugs among patients presenting to a community hospital with STEMI.

Methods:

This was a prospective, single-center, cohort study comprising data from STEMI patients transferred from community hospitals to Hartford Hospital, Hartford, Connecticut, from the years 2000 to 2003. At the time of analysis, patients receiving primary PCI were matched (1:1) with those receiving facilitated PCI, utilizing propensity scores to assure similar demographics. The combined incidence of major adverse cardiac end points (MACE) and total hospital costs was compared between groups. Non-parametric bootstrapping was conducted to calculate CIs for the incremental cost-effectiveness ratio and generate a quadrant analysis.

Results:

Based on 254 propensity score-matched patients (127 facilitated PCI and 127 primary PCI), in-hospital MACE and total hospital costs were reduced by 61.3% and US $4563 (2005), respectively, in patients receiving facilitated compared with primary PCI (P=0.021 and P=NS, respectively). Patients receiving facilitated PCI were more likely to have target lesion Thrombolysis in Myocardial Infarction (TIMI) III (normal) blood flow on cardiac catheterization than those receiving primary PCI (49.6% vs 30.7%; P=0.002). However, the rate of TIMI bleeding was similar in both groups (21.3% in the facilitated PCI group vs 18.9% in the primary PCI group). Nonsignificant reductions were observed in both intensive care unit (ICU) and total length of stay (LOS) (0.8 day and 1.0 day, respectively) compared with the primary PCI group. Bootstrap analysis revealed that of 25,000 samplings, facilitated PCI would likely be both more effective and less costly 94.6% of the time.

Conclusions:

The use of facilitated PCI in STEMI patients who initially presented to community hospitals and were transferred for PCI appeared to significantly reduce the incidence of MACE, and increase the likelihood of having baseline TIMI III blood flow at time of catheterization. Nonsignificant reductions were observed in total ICU and hospital LOS. However, there did not appear to be a significant effect on the incidence of bleeding in patients receiving facilitated PCI. Bootstrap analysis confirmed that facilitated PCI would be both a more effective and less costly strategy.

References (21)

There are more references available in the full text version of this article.

Cited by (10)

  • The effects of fibrinolytic before referring STEMI patients: A systematic review and meta-analysis

    2017, IJC Heart and Vasculature
    Citation Excerpt :

    A total of 912 studies were identified but only six articles [12–17] met eligible criteria (Fig. 1). Of six included studies, three studies were RCTs [12–14], while the rest were non-RCTs [15–17] with a total of 6523 patients. The characteristics of included studies are shown in Tables 1 and 2.

  • Part 9: Acute coronary syndromes: 2010 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations

    2010, Resuscitation
    Citation Excerpt :

    Most of these studies have been performed in recent years. Eleven studies supported a facilitated PCI strategy (LOE 1538; LOE 2;464,539–541 LOE 3542–544; LOE 5545–547). Thirty studies show no benefit of PPCI over fibrinolysis (LOE 1405,491,548–554; LOE 2555–560; LOE 5451,561–566,567–574).

  • Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials

    2009, American Journal of Emergency Medicine
    Citation Excerpt :

    The study was performed in compliance with the Quality of Reporting of Meta-Analyses (QUORUM) guidelines [11]. Of the 1462 potentially relevant articles initially screened, a total of 7 trial were initially identified [6-7,12-16], and 6 randomized trials [6-7,12-15] were finally included in the meta-analysis (Fig. 1), involving 2684 patients (1403 or 52.3% randomized to combo therapy and 1281 or 47.7% randomized to early Gp IIb-IIIa inhibitors). Characteristics of the included trials are shown in Table 1.

  • Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction. A Comprehensive Review of Contemporary Management Options

    2007, Journal of the American College of Cardiology
    Citation Excerpt :

    Thus, the use of adjunctive glycoprotein IIb/IIIa inhibition may be important to the success of this approach. Additionally, a recent cost-effectiveness study suggests that a facilitated PCI strategy may have the potential for cost benefits in addition to clinical benefits for patients with STEMI being transferred from community hospitals to undergo PCI (97). Although a facilitated PCI approach remains controversial, and is presently regarded as a class IIb recommendation in the ACC/AHA STEMI management guidelines (2), these data nonetheless suggest that there may be benefit in selected instances where tertiary hospitals and community hospitals can develop an integrated care delivery model.

View all citing articles on Scopus
View full text